Author:
ANJAN BERA ,AVIK MAJI ,DEBJANI BANERJEE ,DEBOJYOTI MANNA ,SHILPI ADHIKARY
Abstract
Objectives: Whether to irradicate the para-aortic node prophylactically or not in locally advanced cervical carcinoma in the absence of para-aortic lymphadenopathy, the recommendation varies across guidelines. Extended field radiotherapy may improve overall survival (OS) by better local control of the para-aortic nodal region compared to pelvic RT alone, especially in patients unable to tolerate concurrent pelvic chemoradiotherapy.
Methods: This was a single institutional retrospective study carried out in the department of radiotherapy at NRSMCH, Kolkata. A total of 30 HPE-proven locally advanced cervical cancer patients treated with extended field intensity-modulated radiotherapy (IMRT) were selected for this retrospective study.
Results: Response assessment was done 12–16 weeks after completion of treatment and 26 patients (86%) had complete locoregional responses and four patients had the local disease (14%). The 2-year OS was 86%. The common toxicity was Grade I small bowel toxicity (diarrhea), skin reactions, and Grade I neutropenia, seen in 78%, 63%, and 58% of patients, respectively. Another acute toxicity was Grade I anemia seen in 35% of patients. The common late toxicity was Grade I lower GI (11%).
Conclusions: Extended Field-IMRT is a convenient, feasible, and effective treatment modality for target coverage and para-aortic nodal control with minimal toxicity.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference17 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49. doi: 10.3322/caac.21660, PMID: 33538338
2. Chopra SJ, Mathew A, Maheshwari A, Bhatla N, Singh S, Rai B, et al. National cancer grid of India consensus guidelines on the management of cervical cancer. J Glob Oncol. 2018 Jul;4:1-15. doi: 10.1200/ JGO.17.00152, PMID: 30085891, PMCID: PMC6223405
3. Biswas L, Bera A, Manna D, Mondal S. Epidemiology of cervical cancer: A retrospective study in tertiary health-care center in Kolkata over one decade. Int J Med Sci Public Health. 2019 Nov;8:971-4. doi: 10.5455ijmsph.2019.0925914092019
4. Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G, et al. Locally advanced cervical cancer: A study of 5-year outcomes. Indian J Cancer. 2018 Jan-Mar;55(1):45-49. doi: 10.4103/ ijc.IJC_428_17, PMID: 30147092
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer Version 1. Philadelphia, PA: National Comprehensive Cancer Network; 2023. Available from: https://www.nccn.org [Last accessed on 2023 May 16].